142 related articles for article (PubMed ID: 19638079)
1. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
J Gastroenterol Hepatol; 2009 Jun; 24(6):970-81. PubMed ID: 19638079
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer -- report of 2 cases.
Wolschke C; Goekkurt E; Al-Batran SE; Hossfeld DK; Stoehlmacher J
Onkologie; 2005 Nov; 28(11):589-92. PubMed ID: 16249645
[TBL] [Abstract][Full Text] [Related]
4. [Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity].
Terashima M
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1101-4. PubMed ID: 18633250
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract][Full Text] [Related]
6. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
Kai K; Kitajima Y; Hiraki M; Satoh S; Tanaka M; Nakafusa Y; Tokunaga O; Miyazaki K
Cancer Lett; 2007 Dec; 258(1):45-54. PubMed ID: 17892912
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics and stomach cancer: an update.
Toffoli G; Cecchin E
Pharmacogenomics; 2007 May; 8(5):497-505. PubMed ID: 17465714
[TBL] [Abstract][Full Text] [Related]
8. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
Shitara K; Muro K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Matsuo K
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1311-9. PubMed ID: 20447923
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
Chen JS; Chao Y; Bang YJ; Roca E; Chung HC; Palazzo F; Kim YH; Myrand SP; Mullaney BP; Shen LJ; Linn C
Anticancer Drugs; 2010 Sep; 21(8):777-84. PubMed ID: 20634689
[TBL] [Abstract][Full Text] [Related]
11. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract][Full Text] [Related]
12. [Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy].
Sakurai Y; Furuta S; Sunagawa R; Tonomura S; Inaba K; Shoji M; Nakamura Y; Isogaki J; Komori Y; Uyama I; Kamoshida S; Tsutsumi Y
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1581-7. PubMed ID: 17940372
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
14. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
15. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of stomach cancer.
Toffoli G; Cecchin E
Suppl Tumori; 2003; 2(5):S19-22. PubMed ID: 12914384
[TBL] [Abstract][Full Text] [Related]
17. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
Boisdron-Celle M; Morel A; Gamelin E
Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
Kamoshida S; Shiogama K; Shimomura R; Inada K; Sakurai Y; Ochiai M; Matuoka H; Maeda K; Tsutsumi Y
Oncol Rep; 2005 Nov; 14(5):1223-30. PubMed ID: 16211289
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy.
Nishiyama M; Eguchi H
Adv Drug Deliv Rev; 2009 May; 61(5):402-7. PubMed ID: 19133303
[TBL] [Abstract][Full Text] [Related]
20. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Oeda M; Yoshida K; Sanada Y; Wada Y; Suzuki T; Mizuiri H; Konishi K; Shigematsu H; Tanabe K; Fukushima M
Oncol Rep; 2006 Dec; 16(6):1165-72. PubMed ID: 17089033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
